Clinical trial · Observational
Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer
Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer - an Association With Inflammatory Response and Plasminogen Activation System
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bladder cancer (BC) is one of the most common type of cancer globally. Due to its high incidence rate, high risk of recurrence and progression, and frequent cystoscopy surveillance, BC contributes to major healthcare costs across the world. The goal of this prospective study was to evaluate the prognostic value of novel non-muscle invasive bladder cancer (NMIBC) biomarkers for predicting disease recurrence or progression after radical transurethral resection of bladder tumour (TURBT). The data obtained from this study may help physicians identify patients who are at greater risk of NMIBC recurrence or progression and require close supervision.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biomarkers | — | UNRESOLVED | — |
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Cystoscopy | — | UNRESOLVED | — |
| Non-muscle Invasive Bladder Cancer | — | UNRESOLVED | — |
| Progression | — | UNRESOLVED | — |
| Recurrence | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood serum: sUPAR, PAI-1, IL-8. | Diagnostic Test | — | UNRESOLVED |
| Urine: IL-8, APOE, VEGF. | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients after TURBT with NMIBC
- description
- Patients who underwent successful TURBT with histopathological proof of non-muscle invasive bladder cancer. Blood and urine specimen have been gathered prior to hospital admission during visit in out-patient clinic.
- interventionNames
- Diagnostic Test: Blood serum: sUPAR, PAI-1, IL-8.
- Diagnostic Test: Urine: IL-8, APOE, VEGF.
Primary outcomes (1)
- measure
- Tumour recurrence or progression
- timeFrame
- Up to 1 year
- description
- Tumour recurrence or progression based on histopathological result from specimen from follow-up cystoscopy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed informed consent form * Presence or suspicion of tumour in urinary bladder * Qualification for the first transurethral resection of bladder tumour Exclusion Criteria: 1. age \< 18 years 2. active urinary tract infection 3. active autoimmune disease 4. end-stage renal failure and renal replacement therapy 5. active hepatitis A, B or C 6. active HIV infection 7. pregnancy 8. factors disqualifying the patient from adjuvant treatment (intravesical immunotherapy or intravesical chemotherapy) 9. bladder tumour stage T2 or more, or urothelial tumour in a location other than the urinary bladder 10. other cancer or systemic anticancer treatment carried out up to 5 years ago 11. factors disqualifying the patient from surgical treatment, e.g. coagulopathies 12. lack of patient consent to collection of blood and urine samples and to follow-up visits
References
Publications (1)
- DERIVEDBardowska K, Krajewski W, Kolodziej A, Koscielska-Kasprzak K, Bartoszek D, Zabinska M, Chorbinska J, Kubacki F, Krolicki T, Krajewska M, Szydelko T, Kaminska D. Evaluation of six novel biomarkers for predicting recurrence of non-muscle invasive bladder cancer after endoscopic resection- a prospective observational study. World J Urol. 2025 Feb 10;43(1):114. doi: 10.1007/s00345-025-05485-9. PMID 39928162